Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients.
Sophie LaroumagneJulie TronchettiHervé DutauPhilippe AstoulPublished in: Current oncology (Toronto, Ont.) (2024)
Maintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with Leishmania amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphotericin B was started. Oncologists should bear in mind that visceral leishmaniasis in endemic areas can potentially induce severe and prolonged pancytopenia in immunosuppressed patients, during chemotherapy in particular.
Keyphrases
- drug induced
- bone marrow
- liver injury
- end stage renal disease
- mesenchymal stem cells
- newly diagnosed
- combination therapy
- adipose tissue
- ejection fraction
- ultrasound guided
- squamous cell carcinoma
- clinical trial
- high grade
- peritoneal dialysis
- single cell
- prognostic factors
- radiation therapy
- palliative care
- patient reported outcomes
- cell therapy
- replacement therapy
- advanced cancer
- smoking cessation
- tyrosine kinase